<div id="readability-page-1"><div><p>Artivion (AORT) climbed about 5% after positive analyst commentary related to its On-X mechanical heart valve, with new clinical studies indicating a potentially larger U.S. market and stronger demand among younger patients.</p> <p>See our latest analysis for Artivion.</p> <p>The latest enthusiasm around On-X comes on top of a strong run, with Artivion's share price up sharply this year and a three year total shareholder return of nearly 300 percent signaling sustained momentum rather than a one off spike.</p> <p>If this kind of medical device story has your attention, it could be a good moment to explore other healthcare names using healthcare stocks as a starting point for fresh ideas.</p> <p>But after such a sharp multi year run and a stock now trading close to fresh analyst targets, is Artivion still flying under the radar, or has the market already priced in the next leg of growth?</p> <h2>Most Popular Narrative Narrative: 10.0% Undervalued</h2> <p>With shares last closing at $46.55 against a narrative fair value of $51.71, the storyline points to meaningful upside if its growth path holds.</p> <blockquote> <p><em>Expansion of On-X valve usage supported by new clinical data showing mortality benefits for younger patients and effective cross-selling from AMDS training sessions is enabling Artivion to capture increased market share globally, driving double-digit revenue growth and providing upside to profitability through higher volumes and ASPs.</em></p> </blockquote> <p>Read the complete narrative.</p> <p>Want to see what kind of growth and margin lift could justify that premium future earnings multiple? The projections behind this fair value may surprise you.</p> <p><strong>Result: Fair Value of $51.71 (UNDERVALUED)</strong></p> <p>Have a read of the narrative in full and understand what's behind the forecasts.</p> <p>However, sustained double digit growth is not guaranteed. Regulatory delays and hospital pricing pressure are both capable of quickly undermining bullish earnings and valuation assumptions.</p> <p>Find out about the key risks to this Artivion narrative.</p> <h2>Another View on Valuation</h2> <p>While the narrative framework suggests Artivion is 10 percent undervalued, a simple price to sales lens points the other way. At 5.2 times sales versus 3.1 times for the US medical equipment sector and a 2.7 times fair ratio, the stock screens clearly expensive. Which signal do you trust?</p> <p>See what the numbers say about this price — find out in our valuation breakdown.</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1b02136a-c002-438e-b8ae-537c1534c00c/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1b02136a-c002-438e-b8ae-537c1534c00c/chart/ps-multiple-vs-industry"/><figcaption>NYSE:AORT PS Ratio as at Dec 2025</figcaption></figure><h2> Build Your Own Artivion Narrative</h2> <p>If you want to dive into the numbers yourself and challenge this storyline, you can shape a fresh one in just minutes, Do it your way.</p> <p>A great starting point for your Artivion research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.</p> <h2>Ready for more investing angles?</h2> <p>Before markets move again, put your curiosity to work by scanning fresh opportunities on Simply Wall St's Screener, so promising ideas do not slip past you.</p> <ul> <li>Capture potential multi baggers early by targeting fast growing names among these 3624 penny stocks with strong financials with improving fundamentals and room to scale.</li> <li>Position yourself at the frontier of automation and data by tracking breakthrough innovators across these 25 AI penny stocks pushing real world AI adoption.</li> <li>Lock in quality at a discount by focusing on these 914 undervalued stocks based on cash flows where cash flow strength outpaces the current market price.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

AORT

<p>Artivion (AORT) shares rose 5% following positive analyst commentary on its On-X mechanical heart valve, indicating a larger U.S. market and demand among younger patients. Despite a strong share price increase, Artivion is considered 10% undervalued with a fair value of $51.71. However, regulatory delays and pricing pressures pose risks. The stock's price-to-sales ratio suggests it may be expensive compared to the sector. Investors are encouraged to explore healthcare stocks for new opportunities.</p>

Assessing Artivion (AORT) Valuation After Analyst Upgrades and New On-X Valve Clinical Data